Question? Call us
212-363-7500Choose your preferred way to stay informed of new case launches and settlement deadlines
The filed complaint alleges that IGM Biosciences, Inc. made materially false and/or misleading statements and/or failed to disclose that: IGM issued a press release on January 9, 2025, "announc[ing] a strategic update to halt further development of imvotamab, an IgM-based CD20 X CD3 bispecific antibody T cell engager, and IGM-2644, an IgM-based CD38 X CD3 bispecific antibody T cell engager, for autoimmune diseases." The press release quoted Mary Beth Harler, M.D., the Company's Chief Executive Officer, as stating that "[i]nterim data from the Phase 1b studies of imvotamab in rheumatoid arthritis and systemic lupus erythematosus show that the depth and consistency of B cell depletion is insufficient to meet our high bar for success[.]" Following this news, IGM's stock price fell over 66% on January 10, 2025.
In order to be eligible to join the IGMS class action lawsuit, you must have incurred a loss on shares of IGM Biosciences, Inc. purchased during the class definition listed above.
TOP